NKX3-1 (NK3 homeobox 1) by Song, LN & Gelmann, EP









Atlas Genet Cytogenet Oncol Haematol. 2010; 14(3)  246 
Atlas of Genetics and Cytogenetics 
in Oncology and Haematology 
OPEN ACCESS JOURNAL AT INIST-CNRS 
NKX3-1 (NK3 homeobox 1) 
Liang-Nian Song, Edward P Gelmann 
Herbert Irving Comprehensive Cancer Center, Columbia University, New York, NY 10032, USA (LNS, 
EPG) 
 
Published in Atlas Database: March 2009 
Online updated version: http://AtlasGeneticsOncology.org/Genes/NKX31ID41541ch8p21.html 
DOI: 10.4267/2042/44701 
This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 2.0 France Licence. 
© 2010 Atlas of Genetics and Cytogenetics in Oncology and Haematology 
 
Identity 
Other names: NKX3 BAPX2; NKX3A; NKX3.1 
HGNC (Hugo): NKX3-1 
Location: 8p21.2 




The gene has two exons and one intron. 
Transcription 
Transcription takes place in a centromere --> telomre 
orientation. The length of the processed mRNA is 





234 amino acids; 35-38 kDa, contains one N- 
terminal domain (residues 1-123), one homeo-domain 
(residues 124-183), and one C-terminal domain 
(residues 184-234). 
Expression 
Expression is restricted to the adult murine prostate and 
bulbourethral gland. During early murine 
embryogenesis NKX3-1 expression has also been 
detected in developing somites and testes. In the adult
human expression is seen in prostate epithelium, testis, 




Binds to DNA to suppress transcription. Interacts with 
transcription factors, e.g. serum response factor, t  
enhance transcriptional activation. Binds to and 
potentiates topoisomerase I DNA resolving activity. 
Acts as prostate tumor suppressor. 
Homology 
Homeodomain protein with membership of the NKX 
family. 
 
The gene for NKX3-1 comprises two exons of 334 and 2947 bp, respectively. The length of the intron is 964 bp. Positions of start and 
stop codons are indicated. 
 
NKX3-1 contains two exons encoding a 234-amino acid protein including a homeodomain (grey). 
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Mutations 
Germinal 
Twenty-one germ-line variants have been identified in 
159 probands of hereditary prostate cancer families. 
These variants were linked to prostate cancer risk in 
hereditary prostate cancer families. For example, th  
C154T (11% of the population) polymorphism 
mutation is associated with prostatic enlargement and 
prostate cancer risk. A T164A mutations in one family 
cosegregates with prostate cancer in three affected 
brothers. For a more complete list of identified 








Prostate cancer is the most commonly diagnosed cancer 
in American men and the second leading cause of 
cancer-related deaths. Prostate cancer predominantly 
occurs in the peripheral zone of the human prostate, 
with roughly 5 to 10% of cases found in the central 
zone. Disease development involves the temporal and 
spatial loss of the basal epithelial compartment 
accompanied by increased proliferation and 
dedifferentiation of the luminal (secretory) epithelial 
cells. Prostate cancer is a slow developing disease that 
is typically found in men greater than 60 years of age 
and incidence increases with increasing age. 
Prognosis 
PSA test combined with digital-rectal exams are used 
to screen for the presence of disease. If the digital-
rectal exams are positive, additional tests including 
needle core biopsies are taken to assess disease stage 
and grade. Patients with localized, prostate-restricted 
disease are theoretically curable with complete removal 
of the prostate (radical prostatectomy). Patients with 
extra-prostatic disease are treated with hormone 
(androgen ablation) therapy, radiation, and/or 
antiandrogens; however, no curative treatments are 
available for nonorgan confined metastatic disease. 
Cytogenetics 
Various forms of aneuploidy. 
Oncogenesis 
Nkx3.1 plays an essential role in normal murine 
prostate development. Loss of function of Nkx3.1 leads 
to defects in prostatic protein secretions and in ductal 
morphogenesis. Loss-of-function of Nkx3.1 also 
contributes to prostate carcinogenesis. For example, 
Nkx3.1 mutant mice develop prostatic dysplasia. 
Nkx3.1 loss potentiates prostate carcinogenesis in a 
Pten+/- background. Further-rmore, by a variety of 
mechanisms NKX3.1 expression is reduced in 
noninvasive and early stage human prostate cancer, 
suggesting that its decreased expression is one of the 
earliest steps in the majority of human prostate cancers. 
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